<i>PIK3CA</i> Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2+ Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype
Valentina Guarneri(Istituto Oncologico Veneto), PierFranco Conte(University of Padua), Roberto D’Amico(University of Modena and Reggio Emilia), Matteo Curtarello(Johannes Gutenberg University Mainz), Giancarlo Bisagni, Loredana Urso(Istituto Oncologico Veneto), Oriana Nanni(National Institutes of Health), Antonino Musolino(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Enrico Orvieto(AULSS 2 Marca Trevigiana), Antonio Frassoldati(Italian Oncology Group of Clinical Research), Laia Paré(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Luigi Cavanna(University of Pavia), Francesco Giotta(Istituto Tumori Bari), Núria Chic(Breast Cancer Research Foundation), Maria Vittoria Dieci(Istituto Oncologico Veneto), Gaia Griguolo(University of North Carolina at Chapel Hill), Alba A. Brandes(Istituto delle Scienze Neurologiche di Bologna), Federico Piacentini(Azienda Unita' Sanitaria Locale Di Modena), Aleix Prat(Hospital Clínic de Barcelona), Ornella Garrone(Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo), Elena Bertone, Anita Rimanti(Azienda Ospedaliera Carlo Poma)
Cited by 21
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
|Breast Cancer Research|2010|2.1k
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
|IRIS UNIMORE (University of Modena and Reggio Emilia)|2005|1.6k
4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
|Annals of Oncology|2018|1.2k